Royalty Pharma (RPRX)

• Market cap: $13.9B
• 1 day: 1.07%
• 5 days: -0.19%
• 1 month: -5.10%
• 3 months: 3.12%
• 6 months: 17.41%
• Year to date: 24.20%
• 1 year: 14.47%
• 5 years: -28.02%
• 10 years: -28.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 99

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

466% more call options, than puts

Call options by funds: $18.1M | Put options by funds: $3.2M

49% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 51

16% more repeat investments, than reductions

Existing positions increased: 157 | Existing positions reduced: 135

5% more funds holding

Funds holding: 390 [Q3] → 409 (+19) [Q4]

3.46% more ownership

Funds ownership: 68.61% [Q3] → 72.06% (+3.46%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 9 (+0) [Q4]

6% less capital invested

Capital invested by funds: $8.7B [Q3] → $8.17B (-$530M) [Q4]